Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 3,342 Shares of Stock

by · The Cerbat Gem

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) CEO Richard Nolan Townsend sold 3,342 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $5.06, for a total value of $16,910.52. Following the sale, the chief executive officer directly owned 336,764 shares of the company’s stock, valued at approximately $1,704,025.84. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

  • On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.69, for a total value of $312,950.00.

Lexeo Therapeutics Price Performance

Shares of LXEO traded up $0.64 during trading hours on Wednesday, hitting $5.12. 1,834,961 shares of the company were exchanged, compared to its average volume of 970,618. The company has a market capitalization of $402.03 million, a PE ratio of -3.53 and a beta of 1.52. The firm has a fifty day simple moving average of $6.00 and a 200-day simple moving average of $7.59. Lexeo Therapeutics, Inc. has a one year low of $2.51 and a one year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Sell-side analysts expect that Lexeo Therapeutics, Inc. will post -1.19 EPS for the current year.

Institutional Trading of Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Affinity Asset Advisors LLC raised its holdings in shares of Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after acquiring an additional 1,850,211 shares in the last quarter. RA Capital Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth about $49,650,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth about $47,299,000. Vestal Point Capital LP lifted its position in shares of Lexeo Therapeutics by 37.7% in the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after buying an additional 1,225,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the second quarter worth about $16,117,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LXEO has been the subject of several recent analyst reports. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.88.

Read Our Latest Research Report on LXEO

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

Featured Stories